HOOKIPA Pharma
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 179
- Market Cap
- $55.9M
- Introduction
HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.
HOOKIPA Pharma Completes Enrollment in Phase 1b Trial of HB-500 for HIV Treatment
• HOOKIPA Pharma has completed enrollment in its Phase 1b clinical trial evaluating HB-500 for HIV treatment, marking a key milestone in the program. • The trial includes 30 participants across five U.S. sites and assesses the safety, tolerability, reactogenicity, and immunogenicity of HB-500 in HIV patients. • HB-500, developed in collaboration with Gilead Sciences, is a therapeutic vaccine designed to induce robust and durable immunity for a potential HIV cure. • Primary completion of the Phase 1b trial is expected in the second half of 2025, with Gilead having the option to further develop the program.
HOOKIPA Pharma's HB-200 Shows Promise in HPV16+ Head and Neck Cancer Treatment
HOOKIPA Pharma's HB-200 (eseba-vec) demonstrates encouraging results in clinical trials for HPV16-positive head and neck cancers, addressing a significant unmet medical need.